acrivastine and pseudoephedrine

medtigo

acrivastine and pseudoephedrine

Brand Name :

Semprex-D

Synonyms :

acrivastine and pseudoephedrine

Class :

Antihistamine

Action and Spectrum

Mechanism of action

acrivastine is an antihistamine that blocks the H1 histamine receptors in the body, thereby reducing allergy symptoms such as itching, sneezing, runny nose, and watery eyes.

pseudoephedrine is a decongestant that narrows the blood vessels in the nasal passages, decreasing swelling and congestion. It also has a mild stimulating effect on the nervous system, which can help to relieve nasal congestion

Spectrum

The spectrum of acrivastine and pseudoephedrine activity is limited to treating allergic symptoms and nasal congestion, respectively. They are commonly used together in over-the-counter cold and flu remedies to provide both symptom relief from nasal congestion and allergies

Dosing & Uses

Drug Interaction

Adverse Reaction

Frequency defined:

1-10%

nervousness

dry mouth

somnolence

insomnia

<1%

dizziness

nausea

pharyngitis

dysmenorrhea

headache

asthenia

dyspepsia

increased cough

Post-marketing reports

palpitations

tachycardia

skin reactions

Black Box Warning

Contraindication / Caution

Contraindications

acrivastine:

People with a known hypersensitivity to acrivastine should avoid taking it.
People with liver or kidney disease may need a lower dose or special monitoring during treatment.
It is not recommended for use during pregnancy and breastfeeding.
People with narrow-angle glaucoma, bladder problems, or prostate enlargement should use it with caution.

pseudoephedrine:

People with high blood pressure, heart disease, or a history of stroke should use pseudoephedrine with caution.
People with diabetes, thyroid problems, or glaucoma should use it cautiously.
It is not recommended during pregnancy, especially in the last trimester, as it may cause harm to the fetus.
People with narrow-angle glaucoma, urinary retention, or severe hypertension should not use it.
People with severe liver or kidney disease should use it with caution or under the guidance of a healthcare professional.

Caution

acrivastine:

People with liver or kidney disease should use acrivastine cautiously and may need a lower dose or special monitoring during treatment.
Alcohol should be avoided while taking acrivastine, as it may increase drowsiness.
People driving or operating heavy machinery should use caution as acrivastine may cause drowsiness.
It may interact with other medications, including sedatives, anticonvulsants, and tricyclic antidepressants, so it is essential to inform your healthcare provider of all medications being taken.

pseudoephedrine:

People with high blood pressure or heart disease should use pseudoephedrine with caution.
It may cause increased heart rate or blood pressure, so blood pressure should be monitored while taking it.
People who have taken a monoamine oxidase inhibitor (MAOI) within the past 14 days should not take pseudoephedrine.
It may interact with other medications, such as certain antidepressants and stimulants, so it is essential to inform your healthcare provider of all medications being taken.
People who have taken pseudoephedrine for an extended period may experience withdrawal symptoms upon stopping use, such as fatigue, irritability, and depression.

Pregnancy / Lactation

Pregnancy consideration: It is not recommended during pregnancy, especially in the last trimester, as it may cause harm to the foetus

Lactation: Excretion of the drug in human breast milk is unknown

Pregnancy category:

Category A: well-controlled and Satisfactory studies show no risk to the fetus in the first or later trimester.

Category B: there was no evidence of risk to the fetus in animal studies, and there were not enough studies on pregnant women.

Category C: there was evidence of risk of adverse effects in animal reproduction studies, and no adequate evidence in human studies must take care of potential risks in pregnant women.

Category D: adequate data available with sufficient evidence of human fetal risk from various platforms, but despite the potential risk, and used only in emergency cases for potential benefits.

Category X: Drugs listed in this category outweigh the risks over benefits. Hence these categories of drugs need to be avoided by pregnant women.

Category N: There is no data available for the drug under this category

Pharmacology

Pharmacology

acrivastine is a second-generation, non-sedating antihistamine that blocks the H1 histamine receptors in the body. By blocking the effects of histamine, acrivastine reduces allergy symptoms such as itching, sneezing, runny nose, and watery eyes

pseudoephedrine is a sympathomimetic decongestant that narrows the blood vessels in the nasal passages, decreasing swelling and congestion. It also has a mild stimulating effect on the nervous system, which can help to relieve nasal congestion

Pharmacodynamics

acrivastine acts as a competitive antagonist at H1 histamine receptors in the body. By blocking the effects of histamine, acrivastine reduces the symptoms of allergies such as itching, sneezing, runny nose, and watery eyes.

pseudoephedrine narrows the blood vessels in the nasal passages, decreasing swelling and congestion. It also has a mild stimulating effect on the nervous system, which can help to relieve nasal congestion.

Pharmacokinetics

Absorption:

Both acrivastine and pseudoephedrine are rapidly and completely absorbed after oral administration. acrivastine reaches its peak plasma concentration 1.1 hours after administration, while pseudoephedrine reaches its peak concentration 1.97 hours after administration. acrivastine has a peak plasma concentration of 227 ng/ml, and pseudoephedrine has a peak plasma concentration of 422 ng/ml

Distribution:

The distribution of acrivastine is 0.46 L/kg and the Vd of pseudoephedrine is 3 L/kg. acrivastine is 50% protein-bound, while pseudoephedrine is minimally protein-bound

Metabolism:

acrivastine is metabolized to a propionic acid metabolite, with 11% of the dose being converted

Elimination/Excretion: Most acrivastine is excreted in the urine (84%), with a smaller portion excreted in the feces (13%). Pseudoephedrine is primarily excreted in the urine (55-75% depending on urine pH). The clearance of acrivastine is 2.9 mL/min/kg, while the clearance of pseudoephedrine is 5.9 mL/min/kg

Adminstartion

Administration

acrivastine and pseudoephedrine are both typically administered orally in the form of a tablet or capsule

The recommended dose of acrivastine for adults is 8 mg, taken three times daily to relieve seasonal allergies or hay fever symptoms. The recommended dose for children over the age of 12 years is the same as for adults. The dose for children aged 6 to 11 years is 4 mg three times a day

The recommended dose of pseudoephedrine for adults is 60-120 mg, taken every 4-6 hours to relieve nasal congestion or sinus pressure associated with colds, flu, or allergies. The maximum daily dose is 240 mg

Patient Information Leaflet

Patient information leaflet

Generic Name: acrivastine and pseudoephedrine

Pronounced: (a-kri-va-steen/ soo-doh-uh-fuh-dreen)

Why do we use acrivastine and pseudoephedrine?

It is used to treat seasonal hay fever symptoms (allergic rhinitis), such as an itchy or runny nose, sneezing, and nasal congestion

acrivastine and pseudoephedrine

No data available for drug.

DRUG INTERACTION

acrivastine and pseudoephedrine

&

acrivastine and pseudoephedrine +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

acrivastine and pseudoephedrine

No data available for drug.

DRUG INTERACTION

acrivastine and pseudoephedrine

&

acrivastine and pseudoephedrine +

Contraindicated

Serious Use Alternative

Monitor Closely

Minor

medtigo

acrivastine and pseudoephedrine

Brand Name :

Synonyms :

Class :

Action and Spectrum

Dosing & Uses

Drug Interaction

Adverse Reaction

Black Box Warning

Contraindication / Caution

Pregnancy / Lactation

Pharmacology

Adminstartion

Patient Information Leaflet

CONTACT INFORMATION

ADDRESS

JOIN THE FASTEST GROWING HEALTHCARE COMMUNITY!

Download our APP

CONTACT INFORMATION

ADDRESS

Taking the Pain out of Your Career

DOWNLOAD APP